Preemptive therapy with gancyclovir for early high-risk CMV infection allows effective treatment with antithymocyte globulin of steroid-resistant rejection after renal transplantation.
van Son
W J
WJ
Department of Internal Medicine, University Hospital, Groningen, The Netherlands.
van den Berg
A P
AP
The
T H
TH
Tegzess
A M
AM
D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000503:physiopathology / Q000517:prevention & control*; D004351:Drug Resistance; D005260:Female; D015774:Ganciclovir / Q000627:therapeutic use*; D006084:Graft Rejection / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D012189:Retrospective Studies
D000961:Antilymphocyte Serum; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D016853:Muromonab-CD3; D016572:Cyclosporine; D011239:Prednisolone; D015774:Ganciclovir